Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein After Maximum Use, Topical Administration of CCP-020 (Diacerein 1% Ointment) to Patients With Epidermolysis Bullosa (EB)

NCT03472287 is registered in ClinicalTrials.gov with Castle Creek Pharmaceuticals, LLC as lead sponsor.

NCT NCT03472287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03472287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein After Maximum Use, Topical Administration of CCP-020 (Diacerein 1% Ointment) to Patients With Epidermolysis Bullosa (EB)
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Completed
Start date
May 18, 2018
Completion date
February 14, 2019
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dystrophic epidermolysis bullosa, epidermolysis bullosa (eb), epidermolysis bullosa simplex, junctional epidermolysis bullosa